GRI Bio, Inc.
GRIGRI Bio is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies that target dysregulated immune responses.
$2.48M-51.6%
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)EPS estimate-$1.20
Competitors
By market cap
Profile
GRI Bio is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies that target dysregulated immune responses. The company's core value proposition lies in its proprietary platform designed to regulate Natural Killer T (NKT) cells to treat serious inflammatory, fibrotic, and autoimmune disorders.
Competitive position
GRI Bio is a pioneer in targeting NKT cells, a niche area of immunology with no currently approved therapeutics specifically targeting these cells.
GeographiesUnited States, European Union
Customer segmentsPatients with Idiopathic Pulmonary Fibrosis, Patients with Systemic Lupus Erythematosus, Strategic pharmaceutical partners
Business modelResearch and Development, IP Licensing
SuppliersContract Manufacturing Organizations (CMOs), Clinical Research Organizations (CROs), Raw material suppliers, Academic research institutions
CustomersSpecialty pharmacies, Hospitals, Strategic commercialization partners
CountryUnited States of America
Listed2023
CEOW. Marc Hertz
SectorHealthcare
IndustryBiotechnology
Websitegribio.com
FilingsSEC EDGAR
Questions, answered.
- What is GRI Bio, Inc.'s market cap?
- GRI Bio, Inc. (GRI) has a market capitalization of $2.5M and trades on XNAS.
- Who are GRI Bio, Inc.'s competitors?
- GRI Bio, Inc.'s key competitors include Genentech, Bristol-Myers Squibb, AbbVie, and others. These companies compete in similar markets and product categories.
- Who does GRI Bio, Inc. partner with?
- GRI Bio, Inc.'s notable partners include JADO Technologies GmbH.
- What subsidiaries does GRI Bio, Inc. have?
- GRI Bio, Inc.'s subsidiaries include GRI Bio Operations, Inc..
- Where is GRI Bio, Inc. headquartered?
- GRI Bio, Inc. is headquartered in United States of America. It has been publicly traded since 2023.